Clinical Trial Update: Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial of docetaxel in newly diagnosed intermediate and high-grade prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Taxotere (docetaxel)

Snippet

Sponsor: John P. Fruehauf | Conditions: Prostate Cancer, Adenocarcinoma of the Prostate | Phase 2 | Status: WITHDRAWN